RSVpreF Vaccine Is Safe, Effective Among Adults Aged 18 To 59 Who Are At High Risk For Severe RSV, Study Suggests

Infectious Disease Advisor (1/3, Nye) reported, “The bivalent respiratory syncytial virus (RSV) prefusion F protein-based (RSVpreF) vaccine is safe and effective among adults aged 18 to 59 who are at high risk for severe RSV, according to study results.” Researchers found that “the frequency of AEs [adverse events] was similar in the RSVpreF (7.1%) and placebo (7.6%) groups.” In the study, “no vaccine-related serious AEs or newly diagnosed chronic medical conditions were reported.” The findings were published in Clinical Infectious Diseases.